Welcome to our dedicated page for Establishment Labs Hldgs SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Establishment Labs Holdings Inc. (NASDAQ: ESTA) provides access to the company’s U.S. regulatory disclosures as a global medical device issuer focused on breast aesthetics and reconstruction. Through these documents, investors can review how Establishment Labs reports its financial condition, operating results, and key corporate agreements.
Core filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company details revenue from its portfolio of breast health, breast aesthetics, and breast reconstruction products, as well as expenses, liquidity, and risk factors. These reports also describe its manufacturing operations in Costa Rica, quality system compliance under ISO 13485:2016 and FDA 21 CFR 820, and its intellectual property position, including patent applications and clinical evidence supporting its devices.
Current reports on Form 8-K are particularly relevant for tracking material events at Establishment Labs. Recent 8-K filings have covered earnings announcements for specific quarters and an amendment to the company’s credit agreement with Oaktree Fund Administration, LLC, including the availability of additional term loan tranches and related liquidity requirements. Such filings help clarify changes in capital structure, borrowing capacity, and other significant developments.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the content of complex filings. Users can quickly understand the implications of new 10-K and 10-Q reports, 8-K current events, and other submissions without reading every page. The platform also surfaces insider transaction disclosures on Form 4, allowing users to monitor equity transactions by Establishment Labs’ directors and officers as reported to the SEC.
Establishment Labs Holdings director Nicholas Sheridan reported acquiring 609 common shares on 09/30/2025 at a price of $40.99 per share. These shares were issued under the company’s 2018 Equity Incentive Plan and represent shares elected to be received in lieu of a quarterly cash retainer under the issuer’s Outside Director Compensation Policy.
After the transaction the reporting person directly beneficially owned 1,076,532 shares. An additional 19,090 shares are noted as indirectly beneficially owned via the reporting person’s spouse. The Form 4 discloses this routine director compensation election and does not show derivative transactions.
Reporting person: Leslie Gillin, a director of Establishment Labs Holdings Inc. (ESTA), acquired common shares as director compensation.
Transaction details: On 09/30/2025 the reporting person received 411 common shares issued under the company's 2018 Equity Incentive Plan at an effective price of $40.99 per share, representing shares elected in lieu of a quarterly cash retainer. Following the issuance the reporting person beneficially owned 15,516 common shares directly. The transaction was reported on Form 4 and signed by power of attorney on 10/01/2025.
JW Asset Management, JW Partners, JW Opportunities Fund, JW GP and Jason G. Wild reported writing and selling 940 call options on Establishment Labs Holdings Inc. (ESTA) on 08/22/2025. Each option contract covers 100 shares, so the transaction represents rights on 94,000 shares with a $42.50 strike and an option price of $2.1802 per share. The reported position shows 94,000 underlying shares associated with the calls and is held indirectly through affiliated entities. The filing identifies the advisor and affiliated entities as joint reporting persons and explains their relationships.
Establishment Labs Holdings director Nicholas Sheridan Lewin reported an indirect open-market purchase of 2,600 common shares of ESTA on August 14, 2025 at $37.85 per share. The acquired shares are held by his spouse, with Lewin reporting indirect beneficial ownership of 19,090 shares and direct ownership of 1,075,923 shares.
Capital Research Global Investors reports beneficial ownership of 1,024,417 shares of Establishment Labs Holdings Inc., equal to 3.5% of 28,917,254 shares outstanding. The filing states that CRGI is a division of Capital Research and Management Company and related investment management entities that provide services under the name "Capital Research Global Investors." CRGI reports sole voting power and sole dispositive power over the 1,024,417 shares.
The filing further certifies the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing is categorized as an investment adviser (Type: IA).
ESTABLISHMENT LABS HOLDINGS INC. director Lewin Nicholas Sheridan reported an open-market purchase of 2,300 common shares at an average price of $34.2955 per share. The newly purchased shares are held indirectly through his spouse. Following this transaction, he reports direct ownership of 1,075,923 common shares and an additional 16,490 shares held indirectly.
Filippo Caldini, who is listed as Chief Executive Officer and a director of Establishment Labs Holdings Inc. (ESTA), reported a purchase of common shares on 08/11/2025. The amended Form 4/A shows a purchase of 2,850 common shares at $35.20 per share, resulting in reported beneficial ownership of 35,245 shares. The transaction is reported with code P and the ownership is listed as direct (D).
The filing is an amendment (Form 4/A) submitted by a single reporting person and was signed on behalf of the reporting person by Rajbir S. Denhoy, Chief Financial Officer, by power of attorney. The document does not state total outstanding shares or the percentage that 35,245 shares represent, so the filing alone does not establish the transaction's materiality to shareholders.
Establishment Labs Holdings insider Filippo Caldini, who serves as both Chief Executive Officer and a director, reported purchases of 2,850 common shares of the company on 08/11/2025. The Form 4 shows a weighted average purchase price of $35.2 and reports total direct beneficial ownership after the transaction of 35,245 shares. The filing states the trades were executed in multiple transactions at prices ranging from $34.00 to $35.00 and that the reporting person will provide a full breakdown of shares purchased at each price upon request. No derivative securities were reported.